Sign up to access all valuation multiples
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
2013
152
LTM Revenue $27.3M
Last FY EBITDA -$39.6M
-$12.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zomedica has a last 12-month revenue (LTM) of $27.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Zomedica achieved revenue of $27.3M and an EBITDA of -$39.6M.
Zomedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zomedica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $27.3M | XXX | $27.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $19.1M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 70% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$39.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -145% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$35.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -128% | XXX | XXX | XXX |
| Net Profit | -$47.0M | XXX | -$47.0M | XXX | XXX | XXX |
| Net Margin | -172% | XXX | -172% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Zomedica's stock price is $0.
Zomedica has current market cap of $43.1M, and EV of -$12.4M.
See Zomedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$12.4M | $43.1M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Zomedica has market cap of $43.1M and EV of -$12.4M.
Zomedica's trades at -0.5x EV/Revenue multiple, and 0.3x EV/EBITDA.
Equity research analysts estimate Zomedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zomedica has a P/E ratio of -0.9x.
See valuation multiples for Zomedica and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43.1M | XXX | $43.1M | XXX | XXX | XXX |
| EV (current) | -$12.4M | XXX | -$12.4M | XXX | XXX | XXX |
| EV/Revenue | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZomedica's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Zomedica's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zomedica's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zomedica and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -145% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 198% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zomedica acquired XXX companies to date.
Last acquisition by Zomedica was XXXXXXXX, XXXXX XXXXX XXXXXX . Zomedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Zomedica founded? | Zomedica was founded in 2013. |
| Where is Zomedica headquartered? | Zomedica is headquartered in United States of America. |
| How many employees does Zomedica have? | As of today, Zomedica has 152 employees. |
| Who is the CEO of Zomedica? | Zomedica's CEO is Mr. Larry Heaton. |
| Is Zomedica publicy listed? | Yes, Zomedica is a public company listed on PINX. |
| What is the stock symbol of Zomedica? | Zomedica trades under ZOMDF ticker. |
| When did Zomedica go public? | Zomedica went public in 2016. |
| Who are competitors of Zomedica? | Similar companies to Zomedica include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Zomedica? | Zomedica's current market cap is $43.1M |
| What is the current revenue of Zomedica? | Zomedica's last 12 months revenue is $27.3M. |
| What is the current EV/Revenue multiple of Zomedica? | Current revenue multiple of Zomedica is -0.5x. |
| Is Zomedica profitable? | Yes, Zomedica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
